Life science investor Syncona (LON: SYNC) has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative.
The London-based firm has committed an initial £12.5 million ($15 million) to Slingshot, with a 100% stake anticipated once the full investment is realized. The current holding value of Syncona’s initial tranche stands at $6.7 million.
Slingshot Therapeutics will focus on advancing early-stage programs identified in academia, offering a centralized structure to provide resources, funding, and operational support.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze